Riccardo Giovannini

This inventor holds 63 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 6 EPO patents, primarily in CCR2 Antagonists (CPC class C07D). Top assignees: Boehringer Ingelheim International Gmbh, Centrexion Therapeutics Corporation, Smithkline Beecham Corporation. Active years: 2003-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Riccardo Giovannini. Retrieved from https://idiyas.com/inventor/riccardo-giovannini

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 63 (Patent Applications = 8)

% Patents Active = 92.1

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 6.1

ph-index = 9

Forward Citations = 254(Granted Patents)

Forward Citations (Not Self Cited) = 189(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Biberach an der Riss, IT (2018)
Verona, IT (2003 - 2023)
Biberach an der Riss, DE (2018 - 2023)

Company Filing History:

44 out of 1,562

Boehringer Ingelheim International Gmbh

patents

9 out of 36

Centrexion Therapeutics Corporation

patents

5 out of 2,198

Smithkline Beecham Corporation

patents

4. 3 out of 24

Convergence Pharmaceuticals Limited

Smithkline Beecham Croporation

patent

Years Active: 2003-2025

Loading Chart...

Areas of Expertise:

CCR2 Antagonists

CNS Disorders

Somatostatin Agonists

Pyrazolo Derivatives

Morpholine Compounds

Heteroarylcarboxamides

Pyrimidine Derivatives

Piperazine Inhibitors

Tricyclic Pyridine

Aryl-Fused Amides

Selective Antagonists

Plasma Kallikrein Inhibitors

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12209094 - CCR2 receptor antagonists and uses thereof (2025-01-28),

2. 11731981 - CCR2 receptor antagonists and uses thereof (2023-08-22),

3. 11691977 - Cyclic ether derivatives of pyrazolo[1,5-A]pyrimidine-3-carboxyamide (2023-07-04),

4. 11376258 - Purine derivatives and the use thereof as medicament (2022-07-05),

5. 11166958 - 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament (2021-11-09),

6. 11155539 - 4-pyridinylmethyl-morpholine derivatives and the use thereof as medicament (2021-10-26),

7. 11104670 - 4-pyrimidin-5-ylmethyl-morpholine derivatives and the use thereof as medicament (2021-08-31),

8. 11046706 - CCR2 receptor antagonists and uses thereof (2021-06-29),

9. 10919898 - Medical use of compound III (2021-02-16),

10. 10875867 - Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide (2020-12-29),

11. 10849907 - Imidazopyridine derivatives and the use thereof as medicament (2020-12-01),

12. 10675268 - Somatostatin receptor subtype 4 (SSTR4) agonists (2020-06-09),

13. 10640486 - Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors (2020-05-05),

14. 10577336 - Morpholine and 1,4-oxazepane amides as somatostatin receptor subtype 4 (SSTR4) agonists (2020-03-03),

15. 10479794 - Cyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide (2019-11-19),

Title: Riccardo Giovannini - Innovator Extraordinaire from Verona

Introduction: Riccardo Giovannini, a distinguished inventor hailing from the charming city of Verona, Italy, has left an indelible mark on the world of technology with his remarkable innovations. With a whopping 62 patents to his name, Giovannini's relentless pursuit of pushing boundaries and creating groundbreaking solutions has solidified his position as a true pioneer in his field.

Latest Patents:

1. CCR2 Receptor Antagonists and Uses Thereof: Giovannini's groundbreaking invention of novel antagonists for CCR2 (CC chemokine receptor 2) has paved the way for the development of medicaments aimed at tackling various conditions and diseases, particularly focusing on pulmonary ailments such as asthma and COPD.

2. Cyclic Ether Derivatives of Pyrazolo[1,5-A]pyrimidine-3-carboxyamide: With this invention, Giovannini introduced spirocyclic ether derivatives of pyrazolo[1,5-a]pyrimidine-3-carboxyamide that serve as potent inhibitors of phosphodiesterase 2. These compounds have shown promise in treating a range of central nervous system diseases and other related conditions, showcasing Giovannini's versatility and ingenuity in the pharmaceutical realm.

Career Highlights: Throughout his illustrious career, Riccardo Giovannini has contributed significantly to renowned companies such as Boehringer Ingelheim International GmbH and Centrexion Therapeutics Corporation. His innovative mindset and dedication to problem-solving have not only propelled these organizations forward but have also cemented his reputation as a top-tier inventor in the tech industry.

Collaborations: Working alongside talented individuals such as Sara Frattini and Christoph Hoenke, Giovannini has thrived in collaborative environments, leveraging collective expertise to drive innovation and bring cutting-edge ideas to fruition. His ability to inspire and lead teams has fostered a culture of creativity and excellence in the projects he has been a part of.

Conclusion: In conclusion, Riccardo Giovannini's exceptional talent, coupled with his insatiable drive for innovation, has reshaped the landscape of technology and pharmaceutical research. His myriad contributions have not only advanced scientific knowledge but have also set a high standard for aspiring inventors worldwide. Giovannini's legacy as a visionary inventor continues to inspire and shape the future of technological advancement for generations to come.

Profile summary based on public USPTO records.